ArticleCancer medicine2025
Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast-Conserving Surgery.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Research-evidence gap analysis of hypofractionated radiotherapy for breast cancer: a bibliometric knowledge graph study.Frontiers in oncology · 2026Pooled it
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
purposeThe objective of this study was retrospectively to compare the efficacy and safety of hypofractionated radiotherapy (HFRT) with a simultaneous integrated boost (SIB) or with a sequential boost (SB) after breast-conserving surgery in patients diagnosed with early breast cancer.
methodsThis study enrolled a total of 343 patients diagnosed with T1-2N0-1 breast cancer who had undergone breast-conserving surgery followed by whole-breast irradiation (WBI) without nodal irradiation, between March 2018 and April 2021. Out of 343 patients, 176 (51.3%) received HFRT-SIB treatment, totaling 15 sessions, while the remaining 167 (48.7%) received HFRT-SB treatment, totaling 18 sessions. Demographic characteristics, skin toxicity, radiation pneumonia, and myelosuppression, were compared in the two groups. Three-year local progression free survival (LPFS) rates were determined using the Kaplan-Meier method and compared using the log-rank test.
resultsThe median follow-up time was 39.7 months (range 24.3-61.3 months). Toxicities rates did not differ significantly in the HFRT-SIB and HFRT-SB groups, including rates of grade 2 skin toxicity (14.8% vs. 13.8%, p = 0.721), Grade 2 radiation pneumonia (2.8% vs. 3.6%, p = 0.355), grades 1, 2 and 3 myelosuppression (12.5%, 5.7% and 1.1%, respectively, vs. 9.6%, 7.8%, and 1.2%, respectively; p = 0.744). Three-year cumulative LPFS rates were similar in the HFRT-SIB and HFRT-SB groups (99.3% vs. 98.6%, p = 0.52). Regional nodal recurrences were observed in one patient in the HFRT-SIB group (after 27.4 months) and in two patients in the HFRT-SB group (after 29.4 and 56.4 months), and a local recurrence was observed in one patient in the latter group after 36.0 months. One patient in the HFRT-SIB group was diagnosed with distant metastases to bone, and one patient in the HFRT-SB group was diagnosed with distant metastases to the liver.
conclusionSimilar efficacy and safety of HFRT-SIB and HFRT-SB after breast-conserving surgery in patients with early-stage (T1-2N0-1) breast cancer. Longer-term follow-up is required to further compare their efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.